Drug Profile
Ropivacaine liposomal - Taiwan Liposome Company
Alternative Names: TLC-590Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Taiwan Liposome Company
- Class Amides; Anilides; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Postoperative pain
Most Recent Events
- 11 Jun 2021 Taiwan Liposome company plans pivotal phase III trial in postoperative pain in the second half of 2021
- 14 May 2021 Taiwan Liposome Company planning end-of-phase-II meetings with the United States Food and Drug Administration (FDA) on the design of the clinical trials and production preparations in June 2021
- 14 May 2021 Taiwan Liposome company intends to submit NDA to the US FDA fir Postoperative pain